Log in to save to my catalogue

Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent...

Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ba87c7a699914c4c8d06cf93ba025fb8

Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI

Publication information

Publisher

Cheshire: Springer Healthcare

More information

Scope and Contents

Contents

Introduction
Recurrent
Clostridioides difficile
infection (rCDI) often occurs after standard-of-care antibiotics. VOWST oral spores (VOS, previously SER-109), an FDA-approved orally administered microbiome therapeutic, is indicated to prevent rCDI following antibiotics for rCDI.
Objective, Design, and Patients
To evaluate safety and...

Alternative Titles

Full title

Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_ba87c7a699914c4c8d06cf93ba025fb8

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ba87c7a699914c4c8d06cf93ba025fb8

Other Identifiers

ISSN

2193-8229

E-ISSN

2193-6382

DOI

10.1007/s40121-024-01007-z

How to access this item